HbS-to-HbA gene-corrected autologous CD34+ hematopoietic stem cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for HbS-to-HbA gene-corrected autologous CD34+ hematopoietic stem cells, covering 2026-03-11 to 2026-03-11. Get the full timeline:
Most recent: Clinical Trial Update: Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease [Phase 1, Phase 2]